Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of Imprime PGG injection with bevacizumab plus paclitaxel and carboplatin in previously untreated advanced non-small cell lung cancer
2008-006780-37Phase 2Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of odetiglucan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Disease control rate. Started Dec 2008; status: completed.
02
Drugs
odetiglucan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006780-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006780-37.